enGene raises $60M via private placement of 6.76M shares at $8.90/share

enGene Therapeutics Inc.

Gross proceeds ~$60M from sale of 6,758,311 common shares at $8.90/share; expected close Oct 29, 2024.
Investors include Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital, Venrock Healthcare.
Net proceeds to fund detalimogene development, pre-commercial activities, DDX platform expansion, and working capital.
Combined with existing cash, expected to fund operating plan into 2027.
Leerink Partners, Piper Sandler, Guggenheim, Wells Fargo acted as placement agents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.